Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib versus ibrutinib in relapsed or refractory CLL/SLL
NL-OMON56379Phase 3Completed
- Sponsor
- BeiGene
- Start
- Aug 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Zanubrutinib with Ibrutinib (2 arms). Primary endpoint: Overall response rate by investigator assessment. Started Aug 2019; status: completed.
02
Drugs
zanubrutinibibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON56379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56379.